0.8382
4.11%
-0.0359
Lineage Cell Therapeutics Inc (LCTX) 最新ニュース
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit - StockTitan
Dendritic Cell Cancer Vaccine Immunotherapy Market Growing Rapidly by-Lineage Cell Therapeutics, AVAX Technologies, DCPr – IndiaPolitics.com - IndiaPolitics.com
Lineage Cell Therapeutics Inc [LCTX] Shares Fall -3.95 % on Thursday - Knox Daily
Lineage Cell Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing Lineage Cell Therapeutics Inc (LCTX)’s Performance - The Dwinnex
Lineage Looking to Restore Sight, Hearing, Movement - San Diego Business Journal
Allogeneic Stem Cells Market on Track for Strong Growth by 2031 | - openPR
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ... - Yahoo Finance
What Makes Lineage Cell (LCTX) a New Buy Stock - Yahoo Finance
ORBCOMM joins Move to -15°C coalition to promote cold chain sustainability - GlobeNewswire Inc.
Are Smart Investors Making the Right Decision? Lineage Cell Therapeutics Inc (LCTX) - SETE News
Baird maintains Outperform rating on Lineage Cell shares - Investing.com India
Understanding the Risks of Investing in Lineage Cell Therapeutics Inc (LCTX) - Knox Daily
Market Insights: Lineage Cell Therapeutics Inc (LCTX)’s Notable Drop of -1.60, Closing at 0.91 - The Dwinnex
Have you been able to find a good deal on Lineage Cell Therapeutics Inc’s shares? - US Post News
Logos Global Management LP Has $4.69 Million Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
LCTXLineage Cell Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium - Business Wire
Raffles Associates LP Increases Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics Inc [LCTX] Investment Guide: What You Need to Know - Knox Daily
Global Autologous Cell Therapy Product Market Projected to Reach USD 40.77 Billion by 2032 with a 16.9% CAGR - 대구포스트
Lineage Cell Therapeutics Reports Successful Preclinical Results for Cell-Based Therapy for Hearing Loss - The Hearing Review
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop - StockTitan
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance - Business Wire
A Guide To The Risks Of Investing In Lineage Cell Therapeutics Inc (LCTX) - Knox Daily
Autologous Cell Therapy Product Market is Estimated to Reach USD 40.77 Billion By 2032 | Vantage Market Research - 대구포스트
Lineage Cell Therapeutics Inc [LCTX] Records 200-Day SMA of $1.0619 - Knox Daily
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Significant Growth in Short Interest - MarketBeat
Allogeneic Stem Cells Market to Witness Huge Growth by 2031 - openPR
Lineage Cell Therapeutics Inc (LCTX) gets rating Initiated from Craig Hallum - Knox Daily
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Coverage Initiated by Analysts at Craig Hallum - Defense World
Lineage Cell Therapeutics stock upgraded to buy on OpRegen potential - Investing.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Craig Hallum - MarketBeat
Lineage Cell Therapeutics CFO buys $9,345 in company stock - Investing.com
Lineage Cell Therapeutics CFO buys $9,345 in company stock By Investing.com - Investing.com UK
A company insider recently bought 10,000 shares of Lineage Cell Therapeutics Inc [LCTX]. Should You Buy? - Knox Daily
Comerica Bank Raises Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics (FRA:BT3) Financial Strength : 5 (As of Jun. 2024) - GuruFocus.com
What is Lineage Cell Therapeutics Inc (LCTX) Stock Return on Shareholders’ Capital? - SETE News
FY2024 Earnings Forecast for Lineage Cell Therapeutics, Inc. Issued By Cantor Fitzgerald (NYSEAMERICAN:LCTX) - MarketBeat
Is Lineage Cell Therapeutics Inc (LCTX) worth investing in despite its undervalued state? - US Post News
Analysts Set Expectations for Lineage Cell Therapeutics, Inc.’s FY2024 Earnings (NYSEAMERICAN:LCTX) - Defense World
Robert W. Baird’s latest rating for LCTX stock - Knox Daily
Lineage Cell Therapeutics Inc (LCTX) Stock: Navigating Drops and Gains - The InvestChronicle
Quarterly Metrics: Quick and Current Ratios for Lineage Cell Therapeutics Inc (LCTX) - The Dwinnex
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Elk Valley Times
LCTX stock touches 52-week low at $0.83 amid market challenges - Investing.com UK
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript - Seeking Alpha
Lineage Cell Therapeutics Inc [LCTX] Shares Rise 1.80% on Thursday - Knox Daily
Lineage Cell: Q2 Earnings Snapshot - CTPost
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - businesswire.com
Cell Theraputics Market Global and Regional Analysis - Economica
Market Recap: Lineage Cell Therapeutics Inc (LCTX)’s Positive Momentum, Closing at 0.91 - The Dwinnex
Cell Therapy Manufacturing Market Size, Growth Opportunities, - openPR
大文字化:
|
ボリューム (24 時間):